283 related articles for article (PubMed ID: 26921265)
1. MMP2 and MMP9 serum levels are associated with favorable outcome in patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant chemotherapy in the BEVERLY-2 study.
Tabouret E; Bertucci F; Pierga JY; Petit T; Levy C; Ferrero JM; Campone M; Gligorov J; Lerebours F; Roché H; Bachelot T; van Laere S; Ueno NT; Toiron Y; Finetti P; Birnbaum D; Borg JP; Viens P; Chinot O; Gonçalves A
Oncotarget; 2016 Apr; 7(14):18531-40. PubMed ID: 26921265
[TBL] [Abstract][Full Text] [Related]
2. Circulating tumour cells and pathological complete response: independent prognostic factors in inflammatory breast cancer in a pooled analysis of two multicentre phase II trials (BEVERLY-1 and -2) of neoadjuvant chemotherapy combined with bevacizumab.
Pierga JY; Bidard FC; Autret A; Petit T; Andre F; Dalenc F; Levy C; Ferrero JM; Romieu G; Bonneterre J; Lerebours F; Bachelot T; Kerbrat P; Campone M; Eymard JC; Mouret-Reynier MA; Gligorov J; Hardy-Bessard AC; Lortholary A; Soulie P; Boher JM; Proudhon C; Charafe-Jaufret E; Lemonnier J; Bertucci F; Viens P
Ann Oncol; 2017 Jan; 28(1):103-109. PubMed ID: 28177480
[TBL] [Abstract][Full Text] [Related]
3. Pathological response and circulating tumor cell count identifies treated HER2+ inflammatory breast cancer patients with excellent prognosis: BEVERLY-2 survival data.
Pierga JY; Petit T; Lévy C; Ferrero JM; Campone M; Gligorov J; Lerebours F; Roché H; Bachelot T; Charafe-Jauffret E; Bonneterre J; Hernandez J; Bidard FC; Viens P
Clin Cancer Res; 2015 Mar; 21(6):1298-304. PubMed ID: 25538259
[TBL] [Abstract][Full Text] [Related]
4. [Systemic treatments of inflammatory breast cancer: an overview].
Monneur A; Bertucci F; Viens P; Gonçalves A
Bull Cancer; 2014 Dec; 101(12):1080-8. PubMed ID: 25475708
[TBL] [Abstract][Full Text] [Related]
5. Relationship between magnetic resonance imaging characteristics and plasmatic levels of MMP2 and MMP9 in patients with recurrent high-grade gliomas treated by Bevacizumab and Irinotecan.
Farina P; Tabouret E; Lehmann P; Barrie M; Petrirena G; Campello C; Boucard C; Graillon T; Girard N; Chinot O
J Neurooncol; 2017 May; 132(3):433-437. PubMed ID: 28265824
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study.
Pierga JY; Petit T; Delozier T; Ferrero JM; Campone M; Gligorov J; Lerebours F; Roché H; Bachelot T; Charafe-Jauffret E; Pavlyuk M; Kraemer S; Bidard FC; Viens P
Lancet Oncol; 2012 Apr; 13(4):375-84. PubMed ID: 22377126
[TBL] [Abstract][Full Text] [Related]
7. Phase II Trial of Bevacizumab Plus Weekly Paclitaxel, Carboplatin, and Metronomic Cyclophosphamide With or Without Trastuzumab and Endocrine Therapy as Preoperative Treatment of Inflammatory Breast Cancer.
Palazzo A; Dellapasqua S; Munzone E; Bagnardi V; Mazza M; Cancello G; Ghisini R; Iorfida M; Montagna E; Goldhirsch A; Colleoni M
Clin Breast Cancer; 2018 Aug; 18(4):328-335. PubMed ID: 29486983
[TBL] [Abstract][Full Text] [Related]
8. Association of matrix metalloproteinase 2 plasma level with response and survival in patients treated with bevacizumab for recurrent high-grade glioma.
Tabouret E; Boudouresque F; Barrie M; Matta M; Boucard C; Loundou A; Carpentier A; Sanson M; Metellus P; Figarella-Branger D; Ouafik L; Chinot O
Neuro Oncol; 2014 Mar; 16(3):392-9. PubMed ID: 24327581
[TBL] [Abstract][Full Text] [Related]
9. Plasmatic MMP9 released from tumor-infiltrating neutrophils is predictive for bevacizumab efficacy in glioblastoma patients: an AVAglio ancillary study.
Jiguet-Jiglaire C; Boissonneau S; Denicolai E; Hein V; Lasseur R; Garcia J; Romain S; Appay R; Graillon T; Mason W; Carpentier AF; Brandes AA; Ouafik L'; Wick W; Baaziz A; Gigan JP; Argüello RJ; Figarella-Branger D; Chinot O; Tabouret E
Acta Neuropathol Commun; 2022 Jan; 10(1):1. PubMed ID: 34980260
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of matrix metalloproteinases (MMP-2 and MMP-9) in patients with lymph node-negative breast carcinoma.
Li HC; Cao DC; Liu Y; Hou YF; Wu J; Lu JS; Di GH; Liu G; Li FM; Ou ZL; Jie C; Shen ZZ; Shao ZM
Breast Cancer Res Treat; 2004 Nov; 88(1):75-85. PubMed ID: 15538048
[TBL] [Abstract][Full Text] [Related]
11. Surgery following neoadjuvant therapy in patients with HER2-positive locally advanced or inflammatory breast cancer participating in the NeOAdjuvant Herceptin (NOAH) study.
Semiglazov V; Eiermann W; Zambetti M; Manikhas A; Bozhok A; Lluch A; Tjulandin S; Sabadell MD; Caballero A; Valagussa P; Baselga J; Gianni L
Eur J Surg Oncol; 2011 Oct; 37(10):856-63. PubMed ID: 21843921
[TBL] [Abstract][Full Text] [Related]
12. Phase II open-label study of bevacizumab combined with neoadjuvant anthracycline and taxane therapy for locally advanced breast cancer.
Clavarezza M; Turazza M; Aitini E; Saracchini S; Garrone O; Durando A; De Placido S; Bisagni G; Levaggi A; Bighin C; Restuccia E; Scalamogna R; Galli A; Del Mastro L
Breast; 2013 Aug; 22(4):470-5. PubMed ID: 23642526
[TBL] [Abstract][Full Text] [Related]
13. AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.
Gianni L; Romieu GH; Lichinitser M; Serrano SV; Mansutti M; Pivot X; Mariani P; Andre F; Chan A; Lipatov O; Chan S; Wardley A; Greil R; Moore N; Prot S; Pallaud C; Semiglazov V
J Clin Oncol; 2013 May; 31(14):1719-25. PubMed ID: 23569311
[TBL] [Abstract][Full Text] [Related]
14. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.
Untch M; Fasching PA; Konecny GE; Hasmüller S; Lebeau A; Kreienberg R; Camara O; Müller V; du Bois A; Kühn T; Stickeler E; Harbeck N; Höss C; Kahlert S; Beck T; Fett W; Mehta KM; von Minckwitz G; Loibl S
J Clin Oncol; 2011 Sep; 29(25):3351-7. PubMed ID: 21788566
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of soluble carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: A biomarker analysis from the geparquinto phase III neoadjuvant breast cancer trial.
Janning M; Müller V; Vettorazzi E; Cubas-Cordova M; Gensch V; Ben-Batalla I; Zu Eulenburg C; Schem C; Fasching PA; Schnappauf B; Karn T; Fehm T; Just M; Kühn T; Holms F; Overkamp F; Krabisch P; Rack B; Denkert C; Untch M; Tesch H; Rezai M; Kittel K; Pantel K; Bokemeyer C; Loibl S; von Minckwitz G; Loges S
Int J Cancer; 2019 Aug; 145(3):857-868. PubMed ID: 30694523
[TBL] [Abstract][Full Text] [Related]
16. Locally advanced breast carcinoma treated with neoadjuvant chemotherapy: are the changes in serum levels of YKL-40, MMP-2 and MMP-9 correlated with tumor response?
Coskun U; Yamac D; Gulbahar O; Sancak B; Karaman N; Ozkan S
Neoplasma; 2007; 54(4):348-52. PubMed ID: 17845129
[TBL] [Abstract][Full Text] [Related]
17. Clodronate treatment influences MMP-2 associated outcome in node positive breast cancer.
Leppä S; Saarto T; Vehmanen L; Blomqvist C; Elomaa I
Breast Cancer Res Treat; 2005 Mar; 90(2):117-25. PubMed ID: 15803358
[TBL] [Abstract][Full Text] [Related]
18. Role of serum VEGFA, TIMP2, MMP2 and MMP9 in monitoring response to adjuvant radiochemotherapy in patients with primary cervical cancer--results of a companion protocol of the randomized NOGGO-AGO phase III clinical trial.
Braicu EI; Gasimli K; Richter R; Nassir M; Kümmel S; Blohmer JU; Yalcinkaya I; Chekerov R; Ignat I; Ionescu A; Mentze M; Fotopoulou C; Pop C; Lichtenegger W; Sehouli J; ;
Anticancer Res; 2014 Jan; 34(1):385-91. PubMed ID: 24403492
[TBL] [Abstract][Full Text] [Related]
19. Predictive and prognostic value of Matrix metalloproteinase (MMP) - 9 in neoadjuvant chemotherapy for triple-negative breast cancer patients.
Wang RX; Chen S; Huang L; Shao ZM
BMC Cancer; 2018 Sep; 18(1):909. PubMed ID: 30241470
[TBL] [Abstract][Full Text] [Related]
20. MMP2 and MMP9 as candidate biomarkers to monitor bevacizumab therapy in high-grade glioma.
Tabouret E; Boudouresque F; Farina P; Barrié M; Bequet C; Sanson M; Chinot O
Neuro Oncol; 2015 Aug; 17(8):1174-6. PubMed ID: 26142442
[No Abstract] [Full Text] [Related]
[Next] [New Search]
